Aditxt, Inc. (ADTX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aditxt, Inc. (ADTX) trades at $0.88 with AI Score 44/100 (Weak). Aditxt, Inc. is a biotechnology company focused on developing technologies to improve immune system health through immune mapping and reprogramming. Market cap: 3K, Sector: Healthcare.
Last analyzed: Mar 2, 2026Aditxt, Inc. (ADTX) Healthcare & Pipeline Overview
Aditxt, Inc. is pioneering immune health management with its AditxtScore platform, offering personalized immune profiling and potential therapies for organ transplantation, autoimmune diseases, and allergies, positioning it at the forefront of immune system-focused healthcare solutions.
Investment Thesis
Aditxt presents a notable research candidate within the biotechnology sector, driven by its innovative approach to immune health management. The company's AditxtScore platform offers a unique value proposition by providing individuals with personalized insights into their immune profiles, potentially leading to early detection and management of immune-related conditions. The development of Apoptotic DNA Immunotherapy (ADi) for organ transplantation, autoimmune diseases, and allergies represents a significant growth catalyst, addressing large and underserved markets. While the company's current financial metrics, including a negative profit margin of -710498.7% and gross margin of -3413.7%, reflect its early stage of development, the potential for future revenue generation through successful commercialization of its products and therapies warrants consideration. Key value drivers include successful clinical trials, regulatory approvals, and strategic partnerships. Investors should note the company's beta of 1.51, indicating higher volatility compared to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- AditxtScore platform offers personalized immune profiling, a novel approach to immune health management.
- Apoptotic DNA Immunotherapy (ADi) targets large markets in organ transplantation, autoimmune diseases, and allergies.
- Strategic licensing agreements with Loma Linda University and Leland Stanford Junior University provide access to key technologies and expertise.
- Change in company name in July 2021 reflects strategic shift and focus on immune health.
- Headquartered in Mountain View, California, a hub for biotechnology innovation.
Competitors & Peers
Strengths
- Innovative AditxtScore platform for personalized immune profiling.
- Proprietary Apoptotic DNA Immunotherapy (ADi) technology.
- Strategic partnerships with leading universities.
- Experienced management team with expertise in biotechnology.
Weaknesses
- Limited financial resources and high cash burn rate.
- Early stage of development and limited commercialization experience.
- Reliance on strategic partnerships for funding and expertise.
- Negative profit and gross margins.
Catalysts
- Clinical trial results for ADi in organ transplantation (Timeline: 12-18 months).
- Regulatory approvals for AditxtScore in new markets (Timeline: 6-12 months).
- Strategic partnerships with pharmaceutical companies (Timeline: Ongoing).
- Expansion of AditxtScore platform with new biomarkers (Timeline: Ongoing).
Risks
- Dilution of existing shareholders through future fundraising efforts.
- High cash burn rate and limited financial resources.
- Regulatory hurdles and clinical trial failures.
- Competition from established biotechnology companies.
- Intellectual property challenges and patent disputes.
Growth Opportunities
- Expansion of AditxtScore Platform: Aditxt can expand the utility of its AditxtScore platform by incorporating additional biomarkers and developing new applications for disease diagnosis and monitoring. The market for personalized diagnostics is projected to reach $133 billion by 2030, presenting a significant opportunity for Aditxt to capture market share through strategic partnerships and product innovation. Timeline: Ongoing.
- Commercialization of Apoptotic DNA Immunotherapy (ADi): The successful development and commercialization of ADi for organ transplantation, autoimmune diseases, and allergies represents a major growth driver for Aditxt. The market for autoimmune disease therapies is expected to reach $150 billion by 2028, offering a substantial opportunity for ADi to generate revenue. Timeline: 3-5 years.
- Strategic Partnerships and Collaborations: Aditxt can accelerate its growth by forming strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers. These partnerships can provide access to funding, expertise, and distribution channels, enabling Aditxt to expand its reach and commercialize its products more effectively. Timeline: Ongoing.
- Geographic Expansion: Aditxt can expand its operations into new geographic markets, particularly in Europe and Asia, where there is a growing demand for advanced immune system therapies. This expansion can be achieved through strategic partnerships, licensing agreements, or direct investment. Timeline: 2-3 years.
- Development of New Immune-Based Therapies: Aditxt can leverage its expertise in immune mapping and reprogramming to develop new therapies for a wide range of diseases, including cancer, infectious diseases, and inflammatory disorders. This diversification can reduce the company's reliance on its existing product pipeline and create new revenue streams. Timeline: 5+ years.
Opportunities
- Expansion of AditxtScore platform into new markets and applications.
- Commercialization of ADi for organ transplantation, autoimmune diseases, and allergies.
- Strategic partnerships with pharmaceutical companies and healthcare providers.
- Geographic expansion into Europe and Asia.
Threats
- Competition from established biotechnology companies.
- Regulatory hurdles and clinical trial risks.
- Intellectual property challenges.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary AditxtScore platform for personalized immune profiling.
- Innovative Apoptotic DNA Immunotherapy (ADi) technology.
- Strategic licensing agreements with leading universities.
- Expertise in immune mapping and reprogramming.
About ADTX
Aditxt, Inc., established in 2017 and formerly known as ADiTx Therapeutics, is a biotechnology company dedicated to enhancing immune system health through innovative immune mapping and reprogramming technologies. The company's core focus revolves around developing tools and therapies that allow individuals to understand, manage, and monitor their immune profiles. Aditxt's flagship product, AditxtScore, is designed to provide individuals with insights into their immune system's status, enabling them to proactively address potential threats or imbalances. In addition to AditxtScore, the company is developing Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that mimics the body's natural process of inducing tolerance to its own tissues. This technology holds promise for treating autoimmune diseases, allergies, and facilitating successful organ transplantation, including skin grafting. Aditxt operates through strategic licensing agreements, including partnerships with Loma Linda University and Leland Stanford Junior University, to advance its research and development efforts. Headquartered in Mountain View, California, Aditxt is committed to transforming immune health management through personalized and innovative solutions.
What They Do
- Develops AditxtScore for immune profiling.
- Creates technologies for immune system health improvement.
- Focuses on immune mapping and reprogramming.
- Develops Apoptotic DNA Immunotherapy (ADi).
- Targets organ transplantation applications.
- Addresses autoimmune diseases and allergies.
Business Model
- Develops and commercializes immune-related diagnostic and therapeutic products.
- Generates revenue through sales of AditxtScore and ADi therapies.
- Forms strategic partnerships and licensing agreements.
- Conducts research and development to expand its product pipeline.
Industry Context
Aditxt operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation and significant growth potential. The increasing prevalence of autoimmune diseases, allergies, and the growing demand for organ transplantation are driving the need for advanced immune system therapies. Aditxt's focus on immune mapping and reprogramming positions it within a niche market that is expected to experience substantial growth in the coming years. Competitors in this space include companies like AIMD, ANL, APLM, ATHA, and BLRX, each pursuing different approaches to immune modulation and therapy. Aditxt's unique approach to personalized immune profiling and targeted therapies differentiates it from its competitors and provides a competitive edge.
Key Customers
- Individuals seeking to understand and manage their immune profiles.
- Patients with autoimmune diseases, allergies, or in need of organ transplantation.
- Healthcare providers and research institutions.
- Pharmaceutical companies seeking to collaborate on immune-based therapies.
Financials
Chart & Info
Aditxt, Inc. (ADTX) stock price: $0.88 (-0.03, -3.30%)
Latest News
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Mar 13, 2026
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Mar 5, 2026
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Jan 22, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADTX.
Price Targets
Wall Street price target analysis for ADTX.
MoonshotScore
What does this score mean?
The MoonshotScore rates ADTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Aditxt, Inc. Healthcare Stock: Key Questions Answered
What does Aditxt, Inc. (ADTX) do?
Aditxt, Inc. is a biotechnology company focused on developing technologies to improve immune system health. Their primary focus is on immune mapping and reprogramming, with their lead product being AditxtScore, a platform designed to allow individuals to understand, manage, and monitor their immune profiles. Additionally, they are developing Apoptotic DNA Immunotherapy (ADi) for treating autoimmune diseases, allergies, and facilitating successful organ transplantation. Aditxt aims to revolutionize immune health management through personalized and innovative solutions.
Is ADTX stock worth researching?
Evaluating whether ADTX stock is worth researching requires considering its potential and risks. The company's innovative approach to immune health management with AditxtScore and ADi presents significant growth opportunities. However, the company's current financial metrics, including negative profit and gross margins, reflect its early stage of development. Investors should carefully assess the company's ability to secure funding, achieve clinical trial success, and navigate regulatory hurdles before making an investment decision. The high beta of 1.51 also suggests higher volatility.
What are the risks of investing in ADTX?
Investing in ADTX carries several risks inherent to early-stage biotechnology companies. A significant risk is potential dilution of existing shareholders through future fundraising efforts, as the company requires capital to fund its research and development activities. The company also faces a high cash burn rate and limited financial resources, which could impact its ability to execute its business plan. Furthermore, regulatory hurdles and the possibility of clinical trial failures pose substantial risks to the successful development and commercialization of its products. Competition from established biotechnology companies and potential intellectual property challenges also present ongoing risks.
What catalysts could move ADTX stock?
Several catalysts could potentially move ADTX stock in the near to medium term. Positive clinical trial results for ADi in organ transplantation would be a significant catalyst, demonstrating the efficacy and safety of the therapy. Regulatory approvals for AditxtScore in new markets could also drive stock appreciation by expanding the platform's reach and revenue potential. Strategic partnerships with pharmaceutical companies could provide access to funding, expertise, and distribution channels, further boosting investor confidence. Ongoing expansion of the AditxtScore platform with new biomarkers could also enhance its value proposition and attract new customers.
What is ADTX stock price target?
As of March 2, 2026, there is no readily available analyst consensus price target for ADTX stock, likely due to its micro-cap status and limited analyst coverage. Determining a fair value estimate would require a detailed analysis of the company's future revenue potential, expenses, and discount rate, considering the inherent uncertainties associated with biotechnology investments. Investors should conduct their own due diligence and consider the company's growth prospects, risks, and financial position when assessing its potential value.
What are the key factors to evaluate for ADTX?
Aditxt, Inc. (ADTX) currently holds an AI score of 44/100, indicating low score. Key strength: Innovative AditxtScore platform for personalized immune profiling. Primary risk to monitor: Dilution of existing shareholders through future fundraising efforts. This is not financial advice.
How frequently does ADTX data refresh on this page?
ADTX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ADTX's recent stock price performance?
Recent price movement in Aditxt, Inc. (ADTX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative AditxtScore platform for personalized immune profiling. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics reflect the company's current stage of development and may not be indicative of future performance.
- Investment in micro-cap stocks carries significant risks.